Yes, in the future. But more immediate competition is Avastin, which met primary endpoint PFS in PROC regardless of folate receptor from a ph3 study earlier this year. They are in discussion with EMA Regarding filing MAA. They are not planning to file in US yet because they are waiting for OS next year.
Market Data 
Markets 
AI
